Key result
Naftidrofuryl exhibited a 25- to 50-fold lower binding affinity and lower functional potency at the 5-HT2A receptor compared to sarpogrelate, as well as lower inverse agonist activity.
Absolute Event Rate: 6.2% vs 7.6%
p-value: p=<0.05
Naftidrofuryl exhibits lower binding affinity, functional potency, and inverse agonist activity at the 5-HT2A receptor compared to sarpogrelate, which may explain differences in their pharmacological profiles for treating peripheral arterial disease.
May explain PAD efficacy differences; animal data leave clinical relevance of 5-HT2A inverse agonism open.
Naftidrofuryl is a peripheral vasodilator that has been clinically used in the treatment of intermittent claudication and dementia. It has 5-hydroxytryptamine 2 (5-HT(2)) antiserotonergic activity and selectively binds with the 5-HT(2) receptor. The purpose of the present study is to assess the binding affinity and functional potency of naftidrofuryl to the 5-HT(2A) receptor, to find out the inverse agonist activity of this compound at a constitutively active mutant of 5-HT(2A) receptor, and finally to compare the findings with those of sarpogrelate. The investigation showed that the binding affinity (pK(i)) of naftidrofuryl was decreased 25- or 50-fold compared to sarpogrelate in the wild-type 5-HT(2A) receptor or Cys322Lys mutant receptor, respectively. Moreover, the functional potency (pK(b)) of naftidrofuryl was much lower compared to sarpogrelate at the 5-HT(2A) receptor. In addition, inverse agonist activity of naftidrofuryl was lower compared with sarpogrelate at the constitutively active mutant receptor. Thus, the data of the present study would be very important for the clarification of interaction sites of naftidrofuryl to 5-HT(2A) receptors and also may help to understand the mechanism of inverse agonist activity at the constitutively active mutant receptor.
No takes yet. Share an insight, caveat, or question.
Aly et al. (2009) studied this question. Naftidrofuryl vs. Sarpogrelate was evaluated on Binding affinity (pKi) to wild-type 5-HT2A receptor (p=<0.05). Naftidrofuryl exhibited a 25- to 50-fold lower binding affinity and lower functional potency at the 5-HT2A receptor compared to sarpogrelate, as well as lower inverse agonist activity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: